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Abstract 
A need exists for a breast cancer risk identification paradigm that utilizes relevant demo-
graphic, clinical, and other readily obtainable patient-specific data in order to provide indi-
vidualized cancer risk assessment, direct screening efforts, and detect breast cancer at an 
early disease stage in historically underserved populations, such as younger women (under age 
40) and minority populations, who represent a disproportionate number of military benefi-
ciaries. Recognizing this unique need for military beneficiaries, a consensus panel was con-
vened by the USA TATRC to review available evidence for individualized breast cancer risk 
assessment and screening in young (< 40), ethnically diverse women with an overall goal of 
improving care for military beneficiaries.  In the process of review and discussion, it was 
determined to publish our findings as the panel believes that our recommendations have the 
potential to reduce health disparities in risk assessment, health promotion, disease preven-
tion, and early cancer detection within and in other underserved populations outside of the 
military.  This paper aims to provide clinicians with an overview of the clinical factors, evi-
dence and recommendations that are being used to advance risk assessment and screening for 
breast cancer in the military. 
Key  words:  breast  cancer,  screening,  personalized  medicine,  mammography,  Bayesian  Belief 
Networks, machine learning, Gail model, risk assessment 
INTRODUCTION 
The United States military serves a large number 
of  beneficiaries  with  a  disproportionate  share  of 
young (<40), ethnically diverse women.  As part of 
our ongoing commitment to improve the quality of 
care  for  our  beneficiaries,  we  convened  an  expert 
panel  of  military  and  military-affiliated  experts  to Journal of Cancer 2011, 2 
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review the possibility of a personalized breast cancer 
risk  assessment  paradigm  relevant  to  young,  ethni-
cally diverse women that is based on readily obtaina-
ble clinical measures.  This has yet to be developed 
and  represents  an  important  need  in  the  battle  to 
identify breast cancer early. Given the proportion of 
young  and  minority  women  in  our  nation‟s  armed 
services, addressing this need is considered a priority.  
The  development  of  such  a  screening  paradigm,  if 
proven  efficacious,  could  have  an  unprecedented 
impact  on  breast  cancer  outcomes  in  our  service-
women; both by detecting already present cancers in 
young women, as well as raising awareness of and 
compliance  with,  annual  screening  mammography 
after age 40. This consensus report of our panel re-
views current evidence for the development of such a 
screening paradigm in the context of existing screen-
ing approaches, along with potential means by which 
one could be achieved. 
 Breast  cancer  is  the  most  common 
non-skin-related epithelial cancer, and second leading 
cause  of  cancer  mortality  among  women  [1].  There 
were over 60,000 in situ and nearly 200,000 invasive 
breast cancers diagnosed in the United States in 2009, 
and approximately 40,000 deaths from breast cancer. 
[3]  Both  incidence  and  mortality  related  to  breast 
cancer increase with age, making it the most signifi-
cant predisposing risk factor for the development of 
this  malignancy  [2].  Although  the  absolute  risk  of 
breast cancer in women under the age of 40 is low 
(~1.1 - 3.0/1,000 women; Table 1), over 25,000 young 
women under 45 years old are diagnosed with breast 
cancer each year, and this disease remains the leading 
cause of cancer-related death in women aged 15-34 
years [3, 4, 5]. During the early 1980s incidence rates 
of  breast  cancer  increased  in  women  under  age  50, 
and have remained fairly stable in women in this age 
group since the mid-1980s. However, the incidence of 
disease in women under age 40 is increasing and may 
be underestimated [3, 6]. Every year, over 10,000 new 
breast cancer cases are detected in women under the 
age  of  40.  Over  90%  of  these  occur  among  women 
aged 30-39 years and on average 7.5 per every 10,000 
in this age group die as a result of breast cancer every 
year (about 1,200 deaths annually) [3]. 
For women less than age 45, African American 
women are more likely to be diagnosed with breast 
cancer than are other ethnic groups. This is also true 
of young women in active military service, where the 
prevalence  of  breast  cancer  in  African  American 
women exceeds that of all other race/ethnic groups 
for each age category under 40 (Table 2). After age 45 
white  women  have  a  higher  prevalence  of  breast 
cancer [3]. Among women between the ages of 30-39, 
27% of white women versus 40% African American 
women are diagnosed with Stage II or higher disease 
[3]. African American women are diagnosed at later 
stages of disease; hence, with more invasive cancers 
exceeding 5cm in size, with regional nodal metastases, 
and with disease dissemination to distant sites [3, 16]. 
Although white women have higher incidence rates 
after age 45, African American women are more likely 
to die of disease at every age. For women 30-39 years, 
African  American  women  are  almost  twice  more 
likely to die than are white women (6.6 versus 12.8 per 
10,000 women) [3, 16]. 
Table 1: Prevalence of breast cancer in women under age 40 in US cancer screening studies 
Number of 
patients 
Number of 
breast cancers 
Prevalence per 
1,000 women 
Sensitivity of 
Mammography 
Mammography detected 
prevalence (can-
cers/1,000 women) 
Reference 
4,402  5  1.1  0.82  0.9  Destouet & Sherman, 1997 [33] 
7,308  22  3.0  0.77  2.3  Kerlikowski et al. 1996 [34] 
43,906  78  1.8  0.68  1.2  Kerlikowski et al. 2000 [35] 
11,128  162  1.5  0.85  1.2  Bobo et al. 2000 [36] 
Table 2: Incidence of breast cancer in active duty military women, 2000-2009 
Race/ Ethnicity  Incidence of breast cancer/1,000 female person years age category (years)  Total 
   <20  20-24  25-29  30-34  35-39  >=40    
White  0.09  0.16  0.20  0.65  1.32  3.24  0.61 
Black  0.17  0.23  0.33  0.91  1.34  3.15  0.77 
Other  0.07  0.17  0.23  0.59  1.19  2.51  0.46 
Total  0.11  0.18  0.24  0.73  1.31  3.14  0.64 
Search elements: all ages, race/ethnicity, military rank and service with primary (first occurrence) breast cancer diagnosed in the ambulatory 
setting: time period 2000-2009 
Based on a total population 2.02 million (1.1 White, 0.61 Black, 0.29 other race/ethnicity in millions) 
Source: 2000-2009 Defense Medical Epidemiologic Database, Accessed 25 Nov 2010 at http://www.afhsc.mil/aboutDmed Journal of Cancer 2011, 2 
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It is for these reasons that a an expert panel was 
convened by TATRC to discuss: (1) disease preven-
tion (e.g., through weight gain and obesity avoidance, 
regular  physical  activity,  minimized  alcohol  con-
sumption  and  exogenous  hormone  use,  chemopre-
vention in at-risk women); (2) improved breast cancer 
early risk stratification recognizing ethnic disparities 
in breast cancer; and, (3) earlier disease detection in 
women  under  40.  The  principal  benefits  of  breast 
cancer screening are down-staging of cancers (earlier 
diagnosis)  and  reduction  of  cause-specific  mortality 
through  early  intervention.  Down-staging  impacts 
“incremental  cost”  through  reduction  in  cancer 
treatment-related costs, while cause-specific mortality 
impacts  “incremental  effectiveness”  through  in-
creased life years. Screening effectiveness is measured 
by  the  number  of  life  years  saved  as  a  result  of 
screening for breast cancer. Reduction in death due to 
screening is estimated to be 27% for those 50-59 years, 
20%  for  those  40-49  years  and  16%  for  those  30-39 
years [17-23]. The average life years saved by screen-
ing for women 30-39 years is 53 compared to 182 and 
396 for women 40-49 years and 50-59 years, respec-
tively,  based  on  a  cohort  of  10,000  women  in  each 
group. African American women of all ages have a 
greater number of life years saved by screening com-
pared to their white counterparts. It is therefore very 
likely  that  breast  cancer  screening  will  be  more 
cost-effective for African American women compared 
to white women at any age. 
Due to the  inherent  limitations of  mammogra-
phy in younger women, current screening guidelines 
do not recommend routine mammographic screening 
for average-risk women before the age of 40. Conse-
quently,  the  incidence  of  breast  cancer  in  younger 
women is probably underestimated, as many cancers 
developing among women in their fourth decade of 
life  (age  30-39)  are  not  discovered  until  the  first 
screening  mammogram  is  performed,  typically 
around age 40. The relatively increased cancer detec-
tion rate with the first mammogram, as compared to 
all subsequent mammograms, supports this hypothe-
sis [6]. 
The  early  detection  of  breast  cancer  in  young 
women is particularly important because the disease 
biology  is  more  aggressive  in  younger  than  older 
women  [6,  7-10].  Aggressive  cancers  have  a  faster 
growth rate and may present in the interval between 
scheduled  screening  examinations.  Breast  cancer  in 
young women demonstrates aggressive tumor biolo-
gy  evident  in  rapid  tumor  growth  and  a  relatively 
short pre-clinical disease phase. Given that more ef-
fective treatment strategies have been developed for 
breast  cancer  in  younger  women,  screening  could 
favorably impact disease-related survival in younger 
women if it were conducted at shorter intervals than 
in  older  women  [11-15].  A  recent  study  of  over 
240,000 women from the SEER database, who were 
diagnosed with breast cancer between 1988 and 2003, 
found  that  breast  cancer-specific  mortality  was  sig-
nificantly  higher  among  younger  women  (age  <40 
versus  ≥40  years)  [8].  Similar  to  previous  reports, 
younger  women  were  more  likely  to  present  with 
advanced stage disease (given the lack of screening) 
and had distinctly different tumor biology: high pri-
mary tumor grade and large size, estrogen and pro-
gesterone  receptor  negative,  regional  node  positive 
[8]. These findings are consistent with higher mortal-
ity  and  a  seemingly  different  disease  etiology  in 
younger women. 
The  economic  burden  of  delayed  diagnosis  of 
breast  cancer,  particularly  in  younger  women,  is 
enormous. There are approximately 20 million wom-
en between the ages of 30-39 in the U.S. Given a breast 
cancer incidence of 1.5/1000 women, 30,000 cancers 
can be expected in this age group, most of which will 
not  be  diagnosed  until  annual  screening  mammog-
raphy commences in the fifth decade of life.  Many of 
these women in their 30s and 40s are an important 
part of the work force. Hence, the economic costs, as 
well as the emotional cost to families with children, 
are certainly greater when a 35-year old woman dies 
than when a 70-year old woman dies as a result of 
breast cancer. The potential benefits of risk identifica-
tion, targeted screening and early cancer detection in 
those under 40 are correspondingly more substantial. 
A need exists for a breast cancer screening paradigm 
that  can  be  used  along  with  relevant  demographic, 
clinical  and  other  readily  obtainable  patient-specific 
data to provide individualized cancer risk assessment, 
direct screening efforts, and detect breast cancer at an 
early stage in younger women. 
Given the age and ethnic composition of women 
in the military, addressing challenges of risk identifi-
cation  and  screening  in  younger,  ethnically  diverse 
women is a particularly pressing issue in providing 
care  to  our  military  beneficiaries.    It  was  with  this 
challenge  in  mind  that  the  TATRC  expert  panel 
sought to identify the current art, issues, and some 
potential  solutions  with  respect  to  our  beneficiary 
population. 
EVIDENCE – BASED MEDICINE 
Evidence-based  medicine  assimilates  the  best 
available clinical evidence stemming from systematic 
research  and  individual  clinical  expertise  with  the Journal of Cancer 2011, 2 
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“conscientious, explicit and judicious use of current 
best evidence in making decisions about the care of 
patients”  [26].  Levels  of  evidence  extending  from 
bench research to randomized clinical trials and sys-
tematic reviews/meta-analyses enable the physician 
to evaluate available evidence critically related to a 
particular problem (Figure 1) and formulate the fun-
damental basis of clinical decision making for the in-
dividual  patient.  However,  other  factors  must  be 
considered in the course of an individualized clinical 
decision,  such  as  patient  ethnicity,  socioeconomic 
status, risk factors, educational experience, psychoso-
cial issues, and co-morbidities. Ideally, the best level 
of  evidence  should  be  considered  for  a  particular 
clinical problem. However, the reality is that the best 
level of evidence (randomized clinical trials and sys-
tematic reviews/meta-analyses) is not always availa-
ble and all pertinent levels of evidence must be con-
sidered as part of clinical decision making. These de-
cisions  should  also  take  into  account  clinical  path-
ways/algorithms  and  guidelines  stemming  from 
multi-disciplinary  consensus  conferences,  govern-
mental agencies, academic and other specialty-based 
professional organizations (Table 3).  
Schuster, McGlynn, and Brook conducted a sys-
tematic review of healthcare within the United States 
and found significant disparities in quality of care. In 
this  study,  up  to  40%  of  patients  were  not  being 
treated  according  to  evidence-based  best  practices, 
50%  were  not  receiving  recommended  preventive 
care, and 20-30% were receiving care that is contrain-
dicated  (inappropriate,  unnecessary  or  potentially 
dangerous) [27]. This study highlights the significant 
gap between published evidence and clinical practice. 
Moreover, it demonstrates the formidable barriers to 
implementation of evidence informed health promo-
tion, disease prevention and treatment guidelines. A 
need  exists  for  an  evidence  informed  breast  health 
promotion, disease prevention and breast cancer risk 
identification and early detection paradigm that can 
effectively leverage relevant, readily obtainable clini-
cal data from the electronic health records.  
Recognizing this need a consensus panel of ex-
perts  was  convened  to  provide  clinicians  with  the 
clinical factors, evidence, and recommendations that 
will advance risk assessment and screening for breast 
cancer, especially for younger women (under age 40) 
and underserved minority populations, and to sug-
gest future directions for research in this area. In ar-
riving at the practical and clinically relevant recom-
mendations  contained  within  this  document,  the 
panel sought to maintain the highest level of evidence 
available with emphasis on personalized breast cancer 
risk assessment and screening. 
 
 
Figure 1: Evidence-based medicine, levels of evidence 
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Table 3: Guidelines and resources for breast cancer risk identification and screening 
American Cancer Society (Breast Cancer Facts & Figures)  http://www.cancer.org/research/cancerfactsfigures 
Susan G. Komen Breast Cancer Foundation  http://ww5.komen.org/ 
AVON Foundation for Women  http://www.avonfoundation.org/ 
National Cancer Institute: Breast Cancer Risk Assessment Tool  http://www.cancer.gov/bcrisktool/ 
Breast Cancer Research Foundation  www.bcrfcure.org 
Ralph Lauren Center for Cancer Care and Prevention  http://www.ralphlaurencenter.org/ 
Breast Cancer.org  http://www.breastcancer.org/ 
National Breast Cancer Foundation  http://www.nationalbreastcancer.org/ 
 
 
 
BREAST CANCER SCREENING IN YOUNG 
WOMEN UNDER AGE 40 
Annual screening mammography is not recom-
mended for average risk  women under 40 because: 
(1) the prevalence of breast cancer in  women < 40 is 
lower than in older women; (2)  of concerns related to 
repeated exposure to low dose ionizing radiation; (3) 
breast tissue density differs significantly in pre- ver-
sus post-menopausal women such that the sensitivity 
for cancer detection with screening mammography is 
10-15% lower in pre-menopausal women with typi-
cally dense breast tissue; (4) the expense of following 
up the large number of false positive mammograms 
due  to  dense  breast  tissue  confounds;  (5)    it  is  not 
considered cost effective, in view of societal costs of 
performing mammograms on a large patient popula-
tion  with  relatively  low  overall  disease  prevalence; 
and  (6)  its  effectiveness  in  decreasing  breast  cancer 
mortality  in  this  population  has  not  been  demon-
strated.  
The  lower  sensitivity  of  screening  mammogra-
phy for dense breasts impacts age groups in which a 
“life  saved”  often  results  in  “higher”  personal  and 
societal costs in terms of altered life expectancy and 
personal  productivity  [61].  New  technologies  for 
breast  cancer  screening  and  early  detection  such  as 
magnetic resonance imaging have emerged and are 
recommended  for  women  with  a  lifetime  risk  of 
breast  cancer  >20%  relative  to  on  population-based 
norms. Breast MRI is unaffected by breast density, has 
higher sensitivity than screening mammography and 
increases early detection of breast cancer in high-risk 
young women [38, 62]. Only for this high risk popu-
lation is the beneficial yield of breast cancer detection 
considered to be sufficiently high to offset the clinical 
and financial costs associated with mammography or 
MRI. However, as current risk assessment tools are 
limited in women <40, robust methods for screening 
young  women  are  needed  to  identify  individual 
women at high-risk of disease that should be consid-
ered  for  image-based  assessment  of  the  breast  and 
counseling for risk reducing intervention.   
The current screening practice for breast cancer 
in average risk young women under 40 is CBE (Clin-
ical Breast Examination) alone, which is ideally per-
formed  in  conjunction  with  monthly  breast 
self-examination (BSE). However, CBE is not consid-
ered clinically useful, as it: (1) is not a purely objective 
assessment; (2) is difficult to standardize, document 
and compare from year to year; (3) has very limited 
sensitivity for small cancers (as low as 10-17%); and, 
(4) has not been shown to reduce breast cancer mor-
tality in young women [37, 38]. Because the CBE has 
low  diagnostic  sensitivity  for  small  lesions,  most 
breast cancers discovered in this manner have been 
growing for approximately six years [39]. Addition-
ally, the finding that nearly 80% of breast cancers in 
women under age 40 are self-detected after the tumor 
is large enough to be palpable, supports the finding 
that this method of screening is suboptimal [28].  
Only  a  few  clinical  trials  have  addressed  the 
risks and benefits of screening CBE as a method to 
reduce disease-specific mortality. Of the three clinical 
trials conducted in third world countries with limited 
availability  of  population-based  mammographic 
screening, one conducted in the Philippines compar-
ing CBE to usual local practice (no formal screening) 
was inconclusive due to poor patient compliance and 
community  support;  the  randomized  trials  in  Cairo 
and India to determine the efficacy of CBE are still 
ongoing [40-42].  
Following an initial pilot study of 5,000 women 
aged 35-64, the Cairo Breast Cancer Screening Trial 
was initiated as a block randomized controlled clinical 
study of 10,000 women at the Italian Hospital in Cai-
ro,  Egypt  for  women  recruited  by  trained  social 
workers [41]. Study subjects undergo either BSE and 
CBE x1 versus BSE and CBE x2 in a primary health 
clinic.  The  CBEs  are  performed  by  trained  female 
physicians and subjects receive BSE education. This 
study  is  on-going  and  evaluates  breast  cancer  inci-Journal of Cancer 2011, 2 
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dence and diagnostic intervention with more frequent 
BSE/CBE screening.  
A  large  population-based  cluster  randomized 
controlled  trial  was  initiated  in  Mumbai,  India  in 
1998,  which  compares  health  education  alone  pro-
vided by female health workers versus health educa-
tion, BSE and CBE conducted every 2 years for un-
derprivileged  women  aged  35-64  (N>150,000)  in  20 
residential areas (slums) [42]. Women in the interven-
tion group receive four rounds of screening including 
visual  cervical  inspection  for  cervical  cancer  and  8 
years of surveillance. The primary outcome variable 
for this on-going study is breast cancer mortality. 
The applicability of these aforementioned trials 
to women in the United States is questionable given 
the  distinctions  between  the  limited  healthcare  re-
sources  and  restricted  access  to  mammography  in 
Third world study settings. Although recommenda-
tions regarding screening CBE in women under 40 are 
conflicting  [ranging  from  recommendations  of  CBE 
every 3 years for women in 20s and 30s (ACS) to CBE 
not  recommended  for  women  of  any  age  (WHO) 
(Table 4), there is insufficient evidence to recommend 
for or against screening CBE in women <40 [37, 40-42]; 
(Table 5).  
Two large randomized controlled clinical trials 
were conducted, (one in Shanghai, the other in Saint 
Petersburg),  along  with  three  subsequent  me-
ta-analyses,  which  included  these  two  trials  and 
non-randomized  cohort  and  case-control  studies 
[43-47]. The Shanghai trial showed equivalent breast 
cancer mortality in both study groups and the Saint 
Petersburg trial found that although the rate of breast 
cancer detection was higher in women screened with 
BSE, no difference in all-cause mortality was evident 
between the BSE and control groups (Table 6). The 
data  from  these  studies  and  meta-analyses  do  not 
demonstrate a benefit for BSE in terms of breast can-
cer survival, but the Shanghai and Saint Petersburg 
studies did show increased rates of breast biopsy in 
women undergoing BSE [43-47]. 
As for clinical breast examination, recommenda-
tions  for  BSE–based  screening  too  are  inconsistent. 
These  guidelines  vary  from  “BSE  is  optional  for 
women  starting  in  their  20s”  (ACS),  encouraging 
physicians to educate their patients in breast cancer 
detection  and  the  technique  of  BSE  (AMA;  ACOG, 
NCCN),  insufficient  evidence  to  recommend  for  or 
against BSE (AAFP, NCI), to recommendation against 
teaching  BSE  (USPSTF).  The  USPSTF  recommenda-
tion against teaching BSE seems justified based on the 
lack of published data supporting net benefit of BSE 
in reducing breast cancer mortality [37]; (Table 4).  
 
Table 4: Guidelines for the early detection of breast cancer in average risk women under age 40  
Screening method  Frequency  Reference 
Breast 
self-examination 
(BSE) 
Recommended  American College of Obstetricians and Gynecol-
ogists (ACOG); American Medical Association 
(AMA); National Comprehensive Cancer Net-
work (NCCN) 
  The AMA encourages physicians to educate their patients in 
the process of breast cancer detection, emphasizing the tech-
nique of self-examination of their breasts. 
American Medical Association (AMA) Policies on 
Breast Cancer 
  Optional for women starting in their 20s  American Cancer Society (ACS) guidelines for the 
early detection of breast cancer 
  Insufficient evidence   American Academy of Family Physicians (AAFP); 
National Cancer Institute (NCI) 
  Not recommended: The USPSTF recommends against teaching 
BSE. There is moderate or high certainty that the service has no 
net benefit or that the harms outweigh the benefits. 
U.S. Preventive Services Task Force (USPSTF) 
Clinical breast ex-
amination (CBE) 
Recommended every three years for women in their 20s and 
30s 
American Cancer Society guidelines for the early 
detection of breast cancer 
  Recommended annually for women age 40+  ACOG, NCCN, ACS 
  Insufficient evidence: No USPSTF recommendation for women 
<40; however the USPSTF concludes that evidence is lacking 
and the balance of harms and benefits cannot be determined 
for CBE as a supplement to mammography in older women. 
U.S. Preventive Services Task Force 
  Not recommended for women of any age  World Health Organization 
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Table 5: Clinical Breast Examination clinical trials 
Age 
group 
(years) 
Study years  Design and Setting  Protocol  Primary  out-
come 
Secondary  out-
come 
Result and reference 
35-64  1996-1997 
first round 
screening 
RCT; block ran-
domization; 
Manila, Philippines; 
202 health centers in 
12 municipalities 
MAMMACARE in-
struction; Annual CBE 
x 5 versus 
nurse/midwife usual 
practice 
No breast 
cancer mor-
tality report-
ed 
Relative risk not 
calculated due to 
limited (35%) 
diagnostic test-
ing after positive  
CBE 
Inconclusive; low overall 
study  participation 
(“refractory attitude” 
amongst study subjects) 
with frequent drop outs 
after 1st round of 
screening; Sensitivi-
ty=26% and Positive 
Predictive Value=1% of 
screening program;  
Screen detected cases 
were not more advanced 
than others [40] 
39-65  2000-2002 
(Pilot);  
RCT enrolling 
RCT; block ran-
domization; 
Italian Hospital 
region, Cairo, Egypt 
CBE training locally 2 
months before trial; 
CBE/BSE x 2 versus 
CBE/SBE x1 by fe-
male physician 
Breast cancer 
incidence 
Benign biopsies: 
1.2% after 1st 
round 
High rate of 1st and 2nd 
round breast cancer 
detection rate: 8/1,000 
and 2/1,000; Study in 
progress [41] 
35-64  1998 –; 
RCT enrolling 
RCT; cluster ran-
domization; 
Mumbai, India 
CBE training x 5 
months before trial; 
CBE/BSE/Breast 
health education eve-
ry 24 months x4  
versus education alone 
delivered by well 
woman health work-
ers 
Breast cancer 
mortality 
Not available  Study in progress [42] 
 
 
 
 
Table 6: Breast Self-Examination clinical trials 
Age 
group 
(years) 
Study 
years 
Design  and 
Setting 
Protocol  Primary 
outcome 
Secondary  out-
come 
Result and reference 
31-65  1989-2000  RCT: Shanghai, 
China; women 
working in 
factories 
Instruction on breast anatomy 
and 3-step BSE by trained 
factory medical worker with 
instruction reinforcement at 1 
and 3 years and medically 
supervised CBE every 6 
months (women practiced 
supervised BSE 1, 3, 6, and 9 
months after initial instruction 
during year 1 and every 6 
months for next 4 years).  
versus 
No information on breast 
cancer screening 
 
Relative Risk 
(RR) for 
breast cancer 
mortality = 
1.03  
(95% CI, 
0.81-1.31) 
Benign biop-
sies:  
RR = 1.57 
(95% CI, 
1.48-1.68) 
Breast cancer was 
6.5/1,000 women in the 
BSE group and 6.7/1,000 
in control group. Breast 
cancer mortality equiva-
lent in both groups [43].  
40-64  1985-2001  RCT, cluster 
randomization; 
Saint Peters-
burg, Russia; 
women at-
tending clinics; 
n=123,748 
Nurses or providers receive 
3-hour training on BSE prior to 
instructing groups of 5-20 
women. BSE instruction  
with reinforcement every 3 
years provided by the trained 
personnel [CBE with review of 
BSE at annual clinic visits] 
versus  
no instruction;  
 
Relative Risk 
(RR) for all 
cause mor-
tality = 
1.07  
(95% CI, 
0.88-1.29) 
 
Breast cancer 
mortality not 
reported. 
Benign biop-
sies: RR 2.05 
(95% CI, 
1.80-2.33) 
Only 18% reported per-
forming monthly BSE 
within 4 years of enroll-
ment, which prompted 
BSE refresher every 3 
years. Even with BSE 
instruction reinforcement, 
only 58% of women per-
formed monthly BSE.  
 
Various publications from 
this study have unex-
plained inconsistencies in 
data reporting [44] 
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 Breast cancer screening with CBE and BSE is not 
without risk; and, include adverse psychological ef-
fects such as apprehension, anxiety, and concern, as 
well as false negative examination. Fenton et al. as-
sessed the accuracy of CBE in asymptomatic women 
in five states within the U.S. who received CBE within 
1 year of breast cancer diagnosis and who died within 
15  years  of  diagnosis  [48].  Community-based  CBE 
was found to have poor sensitivity (21.6%: 95% CI = 
18.1-25.6%) for the detection of lethal breast cancer. 
The findings of this study suggest high false-negative 
rate of CBE and/or biologically virulent breast cancer 
occurring between screening CBEs. In studies of pop-
ulation-based BSE screening, the rate of benign biopsy 
was  significantly  increased  in  women  undergoing 
BSE than controls (RR 1.57 in the Shanghai PRT and 
RR 2.05 in the Saint Petersburg PRT) [43, 44].  
BREAST CANCER ASSOCIATED RISK 
FACTORS AND IDENTIFICATION OF 
AT-RISK YOUNG WOMEN 
Although  breast  cancer  risk  factors  are  well 
known (e.g., increasing age, family history of the dis-
ease, early menarche, late menopause, breast density, 
age at first full-term pregnancy, exogenous estrogen 
and  progestin  use),  only  a  minority  of  women  that 
develop breast cancer carry a known risk factor, and 
only 5-10% have a documented family history of the 
disease or a genetic predisposition to it. Therefore, ≥ 
90% of women who develop breast cancer do not have 
a  known  risk  factor.  Most  breast  cancers  occur  in 
women with only two non-specific disease-associated 
risk  factors,  namely  age  and  female  gender.  Im-
portantly, due to inherent limitations in clinical breast 
examination  (CBE),  nearly  three-fourths  of  breast 
cancers in women < 45 are identified on breast self 
examination (BSE) [28].  
 Table 7 shows the breast cancer-associated risk 
factors and lifetime relative risk of disease ranges for 
women with  the various  conditions used to recom-
mend early screening in women under age 40. Many 
of  the  risk  factors  are  non-modifiable  –  age,  family 
history  of  breast  and  ovarian  cancer,  breast  cancer 
associated  gene  mutations  (hereditary  mutations  in 
tumor suppressor genes BRCA1 and BRCA2), person-
al history of non-invasive breast cancer or diagnostic 
biopsy  revealing  proliferative  lesions  with  cellular 
atypia or lobular carcinoma in situ (LCIS), history of 
radiation exposure to the thorax (e.g. high-dose man-
tle  radiation  treatment  for  Hodgkin‟s  lymphoma), 
extensive breast tissue density (excess glandular rela-
tive to fatty tissue apparent on mammography), early 
menarche, age at first full-term pregnancy, nullipari-
ty, late menopause, and obesity relating to prolonged 
breast exposure to circulating ovarian hormones. The 
Women‟s  Health  Initiative  trial  demonstrated  that 
estrogen/progestin hormone replacement therapy in 
post-menopausal women is associated with increased 
risk of breast cancer [51]. Some breast cancer risk fac-
tors  (obesity,  breast  feeding,  alcohol  consumption, 
oral  contraception  use,  etc.)  are  modifiable  through 
health promotion and disease prevention  strategies. 
These  strategies  include  regular  physical  activity, 
healthy body weight management, minimizing alco-
hol  consumption,  and  judicious  use  of 
post-menopausal hormones. 
 Statistical  models  (risk  assessment  tools)  are 
currently in use to estimate risk of breast cancer (in-
cluding  but  not  limited  to  Gail  Model,  NCI  Breast 
Cancer  Risk  Assessment  Tool,  Claus  Model, 
BRACPRO, MYRIAD II, Tyrer-Cuzick Model – Inter-
national  Breast  Cancer  Intervention  Study.  These 
models take into account various disease-associated 
risk  factors  (all  include  age  and  family  history  of 
breast cancer amongst 1st degree relatives), but indi-
cations for use vary. For example, BRACPRO is a sta-
tistical  model  used  to  guide  genetic  counselling  in 
women at high risk for developing hereditary breast 
and ovarian cancer. The Tyrer-Cuzick model predicts 
risk of breast cancer based on high risk features and 
makes (and may over-estimate) risk adjustment based 
on history of atypical hyperplasia [52]. The risk esti-
mates provided with models currently used are better 
suited  for  population-based  rather  than  individual-
ized risk calculation. 
One of the most commonly utilized relative risk 
assessment  tools  for  seemingly  average-risk  young 
women is the Gail Model. However, models such as 
this are imperfect [53]. Currently, the only criterion 
generally used to identify high-risk women under 40 
who  could  benefit  from  chemoprevention  is  fami-
ly/genetic  history.  The  value  of  this  screening  ap-
proach is limited by the rarity of breast cancer due to 
known  hereditary  mutations  in  tumor  suppressor 
genes BRCA1 and BRCA2. Better screening methods 
are needed to identify at-risk women <40 who could 
benefit from risk reduction via chemoprevention.  
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Table 7: Lifetime relative risk of breast cancer for women with various conditions commonly used to recommend early 
screening before the age of 40 
Class  Condition  Relative risk  Reference 
Family history  One 1st degree relative   1.7-2.0  Pharoah et al., 2000 [29]; 
Collaborative Group on 
Hormonal Factors in Breast 
Cancer, 2001 [30] 
  Two 1st degree relatives  2.0  Collaborative Group on 
Hormonal Factors in Breast 
Cancer, 2001 [30] 
  Three or more 1st degree relatives  3.9  Collaborative Group on 
Hormonal Factors in Breast 
Cancer, 2001 [30] 
Inherited genetic mutation  BRCA1 or BRCA2  5.7  Schwab et al., 2002 [31] 
 
Histology of breast biopsy  Personal history of  breast cancer   2.0-4.0  Feig et al., 1998 [32] 
  Atypical Hyperplasia   4.0  Feig et al., 1998 [32] 
  LCIS   5.9-12.0  Feig et al., 1998 [32] 
Other high-risk factors  Female; 
Age (65+ vs. <65 years); 
High breast tissue density; 
> 4.0  Breast Cancer Facts & Figures 
2009-2010 [3] 
  High-dose chest radiation; 
High bone density post-menopausal 
2.1 – 4.0  Breast Cancer Facts & Figures 
2009-2010 [3] 
  Personal history of endometrial or ovarian 
cancer; 
Alcohol consumption; 
High socioeconomic status; 
Ashkenazi Jewish heritage 
1.1-2.0  Breast Cancer Facts & Figures 
2009-2010 [3] 
Factors affecting circulating 
hormones 
Age > 30 years at first full-term pregnancy; 
Early menarche (Age <12); 
Late menopause (Age >55); 
No full-term pregnancies; 
Never breastfed a child; 
Recent oral contraceptive use; 
Recent and long-term use of estrogen and 
progestin; 
Obesity (postmenopausal) 
1.1-2.0  Breast Cancer Facts & Figures 
2009-2010 [3] 
 
 
 
BREAST CANCER RISK REDUCTION 
THROUGH CHEMOPREVENTION  
The identification of women who are at high risk 
for the development of breast cancer and may benefit 
from  chemoprevention  is  important.  In  the  NSABP 
P-1 study, Tamoxifen reduced the incidence of breast 
cancer by approximately 50% in at-risk women across 
all study age and risk groups [54]. The NSABP P-1 
study  provided  definitive  evidence  that  chemopre-
vention is an efficacious approach for breast cancer 
risk  reduction  [54].  Subsequent  analyses  suggested 
improved  quality-adjusted  survival  and  cost  effec-
tiveness when Tamoxifen was initiated as early as age 
35 in at-risk (Gail Model 5-year risk ≥1.66) women [55, 
56].  Given  the  rarity  of  breast  cancer  gene  muta-
tion-associated breast cancer and the imperfections of 
clinical risk assessment for the disease, improved in-
dividualized  screening  methods  are  imperative  to 
identify at-risk women <40 who stand to benefit from 
risk reduction via chemoprevention.  
As breast cancer in young women is associated 
with  unfavorable  biological  features  contributing  to 
high  cause-specific  mortality,  early  detection  is  an 
important clinical aim [7, 8, 57]. Women under age 40 
are not referred for early image-based screening un-
less  they  are  identified  as  being  “high  risk”,  which 
represents less than 10% of women [58-62]. “At risk” 
women < 40 with significant family history or genetic 
factors,  are  typically  advised  to  undergo  frequent 
clinical breast and annual screening  mammography 
(MMG) examination and consider chemoprevention. 
While  increased  surveillance  for  “at  risk”  women 
appears beneficial, the value of this approach is re-
stricted by the rarity of breast cancer due to known 
genetic risk factors.   
CONTROVERSY AND UNMET NEEDS IN 
BREAST CANCER SCREENING AMONG 
YOUNG WOMEN  
The issue of breast cancer in younger women has 
unique ramifications for society, particularly in rela-Journal of Cancer 2011, 2 
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tively  young,  ethnically  diverse  female  populations 
such as the United States military which are consid-
ered at-risk. Further, the importance of early detection 
of disease is increased in the military population since 
early stage disease can be treated in a manner which 
allows  servicewomen  to  return  to  duty  swiftly  and 
continue to serve our country.  While there is disa-
greement about tumor growth rates in the literature, 
there is general consensus that early detection of dis-
ease  results  in  breast  cancer  down-staging  and  im-
proved  oncological  outcomes.  New  evidence  on 
chemoprevention  and  the  management  of  breast 
cancer also indicates that an effective screening mo-
dality has the potential to increase survival, with re-
sulting economic and quality of life benefits.  
The current debate in breast cancer screening has 
been  ongoing  for  at  least  15  years  and  is  well  de-
scribed.  In 1997, the NCI convened a Consensus De-
velopment Conference on the subject of breast cancer 
screening in younger women, which failed to produce 
the consensus desired by many: “The [NCI] panel also 
recommended that a woman‟s decision about whether 
to undergo mammography should be based not only 
on  the  scientific  evidence,  but  also  on  her  medical 
history, her perception of risk and benefit, and how 
she deals with uncertainty.  Indeed, while results from 
both meta-analyses and individual trials presented at 
the  meeting  revealed  statistically  significant  breast 
cancer mortality reductions for women aged 40-49 at 
randomization,  it  appeared  that  the  debate  had 
shifted from the lack of statistically significant end-
points to that of risk/benefit and cost effectiveness.” 
[50]  Thus,  much  of  the  debate  centers  on  the 
risk-benefit to the patient and on the cost-effectiveness 
of breast cancer screening.  The debate is compound-
ed by conflicting study results as to the actual effect 
on mortality of breast cancer screening and early de-
tection and new information on the harms associated 
with repeated exposure to ionizing radiation.  With an 
active debate on the relative benefit of screening and 
early detection, a new focus on managing healthcare 
costs, and concerns about radiation exposure, it does 
not appear that the debate will be resolved anytime in 
the near future. 
Hypothetically, the development of less invasive 
screening  methods,  lower  cost  screening  methods, 
methods with a higher degree of accuracy, or all three, 
would have the ability to shift the focus of the debate.  
If the cost of screening, in terms of both dollar costs 
and morbidity risk, were to be substantially lowered, 
this would then alter the cost-benefit equation from 
the cost side.  Further, if the accuracy and/or perfor-
mance of screening technologies were improved (im-
proved sensitivity and/or specificity), this could alter 
the cost-benefit equation from the benefit side. 
Given our commitment to our duty of care to our 
young active servicewomen, the TATRC expert panel 
sought to evaluate technologies and approaches that 
have the potential to alter both the cost and benefit 
sides of the equation. Not only does the composition 
of our population necessitate making these advances 
to provide them the best quality of health promotion 
and cancer care, but the unique nature of the Military 
Health  System  as  a  closed-loop  system  provides  a 
unique environment to develop and evaluate the po-
tential costs and benefits of these types of technologies 
and approaches. 
GOALS IN MILITARY BREAST CANCER 
SCREENING AMONG YOUNG WOMEN  
The over-arching goal in breast cancer screening 
for young women in the military is the development 
of new technologies that can advance the paradigm of 
personalized  breast  cancer  risk  assessment  and 
treatment.  We seek to focus on parameters routinely 
collected as part of standard clinical practice and on 
the use of novel technologies that can either improve 
statistical performance or reduce costs. This is partic-
ularly relevant in view of recent findings suggesting 
that the inclusion of newly discovered genetic vari-
ants  associated  with  breast  cancer  in  existing  risk 
prediction models only has a marginal improvement 
in overall model performance [63]. In evaluating cri-
teria for the adoption of new technologies, the TATRC 
panel identified six key attributes in order to be effec-
tive in improving the current breast cancer risk iden-
tification and screening paradigm: 1) pervasive access; 
2) relatively low cost; 3) low risk to the patient; 4) rel-
atively high accuracy; 5) quality assessment built in 
by design; and, 6) prospective design that supports 
ongoing improvement.  
Pervasive access is the need to develop technol-
ogies that can be made broadly available to as many 
women as possible across the spectrum of socioeco-
nomic classes and access to care. While it is not easy to 
say what these technologies are, we can say what they 
are not. In order to be pervasive, they cannot (a) re-
quire access to capital equipment that is costly and 
protracts new testing, (b) require the training of new 
cadres of health professionals, or (c) radically alter or 
disrupt the current practice workflow or standard of 
practice.  However,  it  is  important  to  note  that  we 
currently  lack  an  acceptable  evidence-informed 
standard of practice for breast cancer risk identifica-
tion and screening in young women. These technolo-
gies could  include screening algorithms, novel ana-
tomic  and/or  functional  imaging  methodologies, 
novel diagnostic tests, or some innovative combina-Journal of Cancer 2011, 2 
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tion  of  existing  imaging,  testing  and  clinical  infor-
matics. 
Relatively  low  cost  technological  innovation 
means that these pervasive technologies must either 
reduce, or minimally impact, current screening pro-
gram-related  costs.  Ideal  risk  identifying  and/or 
screening  technologies  could  achieve  this  goal  by 
providing risk stratification and screening at a signif-
icantly  lower  cost  than  current  methods,  or  by 
providing higher detection rates and fewer false posi-
tives (no significant increase in breast biopsy rate) at 
the current cost per beneficiary. In order to improve 
the current paradigm, cost effectiveness must be con-
sidered concurrently with research and development. 
Low risk to the patient is essential.  The devel-
opment of minimally or non-invasive risk identifica-
tion techniques and technologies is essential in order 
to  improve  risk  stratification  and  early  detection 
while reducing exposure risk to the patient.  An ex-
ample of this imperative is the debate over mammo-
graphic screening in women under 40.  While mam-
mography is a non-invasive, relatively low risk tech-
nology,  it  is  not  minimal  risk,  as  regular  mammo-
graphic screening exposes the beneficiary to radiation. 
This raises the valid concern, given low disease prev-
alence  rates  in  the  population,  of  exposing  large 
numbers of healthy women to unnecessary radiation 
in order to identify one pre-clinical cancer. For exam-
ple, the Age Trial enrolled nearly 161,000 women age 
39-41  who  were  randomly  assigned  to  annual 
screening mammography until age 48 versus control 
(standard practice in the United Kingdom), wherein a 
significant  reduction  in  all-cause  and  breast  cancer 
mortality  was  identified.  However,  the  number 
needed to screen in order to prevent one breast can-
cer-related death over 10 years was 2,512 [64].  Fur-
ther,  screening  in  younger  women  should  be  con-
ducted at shorter intervals in order to derive the ben-
efits of early detection, since the pre-clinical detectable 
phase in young women is shorter than in older and 
post-menopausal  women  [26].    This  creates  a 
“Catch-22”  under  the  current  screening  paradigm, 
where the clinical benefit requires a high level of ex-
posure in a broad population for the detection of very 
few instances of disease.  Hence, developing minimal 
risk  methods  and  technologies  has  the  potential  to 
solve this conundrum. 
Relatively  high  accuracy  means  that  any  new 
technology must, at the very least, improve the cur-
rent sensitivity and/or specificity of the current risk 
screening  paradigm.    When  debating  cost  effective-
ness, it is important to remember that not only can 
costs be controlled, but new technology should pro-
vide  clinically  relevant  improvement  in  screening 
efficacy,  while  reducing  false  positive  events.  With 
improved sensitivity, the cost per detection decreases 
and relative benefit increases. With improved speci-
ficity,  the  psychological  and  physical  costs  of  false 
positives  are  decreased,  as  are  the  risks  associated 
with  unnecessary  imaging  and  invasive  diagnostic 
intervention. 
Quality  assessment  should  be  built  into  these 
systems by design. The traditional paradigm for the 
development of clinical methods and technologies is 
oriented principally toward diagnostic devices – de-
velopment,  evaluation,  study  and  validation.  It  is 
viewed as a finite process toward the development of 
a  commercially  viable,  production  ready  device.  
However,  risk  identification  and  stratification  are  a 
process, and as a process, require ongoing evaluation 
and improvement in order to deliver maximum bene-
fit to our beneficiaries.  Thus, any of the technologies 
and methodologies developed should have processes 
designed for ongoing audit, review, and evaluation.  
An  additional  benefit  of  this  ongoing  evaluation 
would be improved post-market data for the FDA to 
consider  when  evaluating  and  approving  newer 
technologies. 
Prospective  design  to  support  ongoing  im-
provement is the logical counterpart of ongoing qual-
ity assessment. Prospective design means designing 
technologies and methods that are intended to sup-
port  continuous  change  and  quality  improvement. 
The process for future design improvements must be 
built into any new technologies at the outset to ensure 
the continuous improvement of accuracy, reduction of 
cost, and overall quality assurance. These goals can be 
translated  into  a  set  of  criteria  that  can  be  used  to 
measure the efficacy of novel risk identification and 
screening technologies and methodologies. 
CRITERIA FOR EFFECTIVE BREAST 
CANCER SCREENING AMONG YOUNG 
WOMEN  
Criteria for screening effectiveness should mirror 
goals, and can thus be described in six categories: 1) 
access metrics, 2) dollar cost, 3) risk to the patient, 4) 
accuracy  statistics,  5)  quality  statistics  and  metrics, 
and 6) success of ongoing quality improvement. 
As a criterion for success,  access can be meas-
ured in several ways.  First, what types of providers 
and institutions can use the technology? Does it re-
quire investment in capital equipment, sophisticated 
health informatics systems, or personnel? Second, are 
there  geographic  limitations  to  how  the  technology 
can be deployed? Third, how many beneficiaries have 
access to the technology? Journal of Cancer 2011, 2 
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Cost can be measured, at a basic level, as the ac-
tual cost of the technology.  However, cost needs to be 
considered  in  a  complete  sense,  wherein  the  cost 
needs to include incremental costs of additional re-
ferrals or procedures, as well as benefits of early de-
tection  in  at-risk  women,  or  reducing  unnecessary 
procedures  for  low  risk  beneficiaries.  Further,  cost 
should be benchmarked against other existing meth-
ods, and should be adjusted appropriately to account 
for  either  improvements  or  reductions  in  screening 
method sensitivity and specificity. An ideal solution 
should, overall, result in increased disease detection 
through  a  lower  overall  recall  rate  at  reduced  total 
cost. 
Risk must be measured in order to complement 
cost in the cost-benefit analysis of risk identification 
and screening. In order to address the current debate 
over  cost-benefit  of  screening,  any  new  solution 
should present a lower risk level than current “solu-
tions”. The risk level to the individual patient with the 
novel  approach  should  be  lower  or  commensurate 
with existing technology, while substantially lower-
ing aggregate population risk. 
The  measurement  and  evaluation  of  risk  as-
sessment and screening accuracy is critical. In order to 
be  effective,  novel  risk  evaluation  and  screening 
technologies should improve current sensitivity and 
specificity.  This  is  critically  inter-related  with  cost, 
risk, and benefit.  Ideally, novel approaches can im-
prove both sensitivity and specificity;  however it is 
often  the  case  that  technology  must  of  necessity  be 
optimized toward one or the other parameter. We will 
need  to  consider  the  relative  benefit  of  sensitivity 
versus specificity, a calculation which cannot be per-
formed  without  also  understanding  overall  disease 
prevalence, cost, risk, and the clinical benefits of early 
detection. Hence, the groundwork for rigorous pro-
spective study and evaluation of all new technologies 
must  be  established  in  order  to  develop  validated 
metrics for sensitivity and specificity. 
Quality statistics and metrics require the collec-
tion of performance data on an ongoing basis. This 
means that data regarding cost, sensitivity, and speci-
ficity should continue to be collected even after pro-
spective evaluation is completed. Further, data should 
not only be collected on accuracy, referral rates, posi-
tive and negative predictive values, and detection and 
recall rates, but data should also be collected on pat-
terns of use across a broad spectrum of clinical loca-
tions and activity, the quality of user interactions with 
the  technology  and  how  the  technology  influences 
clinical workflow patterns.  The ability to study how 
clinicians and patients interact with novel risk identi-
fication and screening technologies will allow us not 
only  to  improve  the  accuracy  and  quality  of  the 
screening programs, but to identify design elements 
that can improve the user experience and encourage 
proper  use  of  the  technology,  with  the  aim  of  ad-
vancing clinical decision support. 
Finally, we must be able to demonstrate that the 
criteria and metrics described above can be reincor-
porated  into  an  improved  set  of  technologies  and 
methods,  i.e.,  success  of  on-going  quality  improve-
ment. 
FOCUS AREAS OF OPPORTUNITY TO 
IMPROVE BREAST CANCER SCREENING 
AMONG YOUNG WOMEN  
Based  on  our  assessment  of  needs,  goals,  and 
criteria  for  success,  our  working  group  identified 
three  promising  areas  of  development  for  the  next 
generation  of  breast  cancer  risk  assessment  and 
screening: 1) improved algorithmic screening; 2) de-
velopment  of  novel  circulating  tumor  cell  (CTC) 
evaluations; and, 3) development of novel biomarkers 
of disease. 
Improved algorithmic screening consists of the 
use of advanced statistical algorithms to improve the 
interpretation  of  readily  available  clinical,  demo-
graphic, and risk factor information.  There is a tre-
mendous  amount  of  information  available  through 
the  clinical  record,  patient  history  and  patient  de-
mographics; however, we have confined our efforts 
pursuant  to  risk  stratification  to  relatively  simple, 
limited models and algorithms. Early work indicates 
that  enhanced  risk  stratification  algorithms  can  be 
used to enhance referral through increased access at 
low  cost,  with  improved  sensitivity  and  specificity. 
We have recently demonstrated proof of concept for 
using  clinical  data  from  a  prospective  pilot  breast 
cancer screening study of young women (n=591) to 
train,  test  and  cross  validate  a  Bayesian  Belief  Net-
work  model  (Figure  2)  [65].  Initial  cross-validation 
results are hypothesis-generating and appear prom-
ising; area under the receiver operating characteristic 
curve for benign and malignant biopsy outcomes was 
0.88 and 0.97, and positive predictive value was 97% 
and 42%, respectively, suggesting that the BBN model 
may provide clinically useful individualized risk es-
timates based on data collected as part of breast can-
cer screening [65].  
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Figure 2: Bayesian Belief Network model, proof of concept for using clinical data from a prospective pilot breast cancer 
screening study of young women to train, test and cross validate a Bayesian classifier. Primary outcome variable is breast 
biopsy histopathology (benign, pre-malignant, malignant) 
 
 
Novel applications of CTCs also have the prom-
ise to provide an additional tool for improving risk 
stratification and screening. While CTCs require spe-
cialized  expertise  and  equipment,  if  used  properly 
they could serve in a very complementary role to the 
development of novel algorithms and biomarkers as 
well  as  existing  imaging  technologies  [66-72].  CTCs 
are cells that have detached from a primary or meta-
static  tumor  and  entered  the  peripheral  circulation.  
CTCs should not be identified in patients without an 
epithelial  malignancy  [66].  Several  methodologies 
have been developed to detect and characterize dis-
seminated tumor cells (DTCs), as they are called in 
bone marrow, or CTCs in peripheral blood of cancer 
patients.  These  methodologies  fall  under  two  main 
categories: immunological based assays and molecu-
lar based assays. Although these approaches can be 
used directly, an enrichment step prior to the detec-
tion is preferred. A number of methodologies exist for 
enriching rare cancer cells, including density gradient 
separation  to  enrich  for  nucleated  cells  (i.e.,  Ficoll 
gradient  separation),  and  magnetic  cell  separation 
either  targeting  the  cancer  cell,  positive  immuno-
magnetic  cell  separation  (PIMS),  or  negative  im-
munomagnetic cell separation (NIMS), where normal 
blood cells are targeted.  Unfortunately, most of the 
reported  studies  using  some  form  of  magnetic  cell 
separation to separate or enrich rare cancer cells do 
not  provide  data,  or  complete  data,  on  the  perfor-
mance of the magnetic separation step. Consequently, 
it makes comparison of the performance of technolo-
gy, as well as the overall study, difficult or impossible.  
The  current  model  of  tumor  biology  identifies 
metastasis as the final step in a linear model of cancer 
progression. Metastases are thus believed not to occur 
until  tumors have reached an adequately large size 
and  acquired  additional  mutations  that  allow  these 
mutated cells to disseminate and grow at distant sites 
(the  „emancipated  cell‟).  However,  current  clinical, 
epidemiological,  and  experimental  data  refute  this 
model [66, 73-85] and suggest that systemic spread is 
an  early  event  in  breast  cancer,  possibly  occurring 
prior to ductal carcinoma in situ [80].  
CTCs  are  identifiable  in  patients  without  de-
tectable cancer and may be a potential early disease 
marker  [86-89].  Reliable  and  accurate  detection  of 
these CTCs is now possible with a simple peripheral 
venous blood draw. A study has been initiated within 
the DoD, which hypothesizes that women with CTCs 
and no other clinically apparent signs of malignancy 
have  clinically  undetectable  disease  (Walter  Reed 
Army Medical Center Department of Clinical Inves-
tigation Protocol: Circulating Tumor Cells (CTCs): A 
potential  screening  test  for  clinically  undetectable Journal of Cancer 2011, 2 
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breast  carcinoma;  PI:  Thomas  A.  Summers).  This 
study  will  attempt  to  validate  the  CTC  detection 
technology as a breast cancer screening test and ac-
quire data to determine the clinical validity and utility 
of  this  proposed  screening  methodology  on  a  rela-
tively young, ethnically diverse population who are 
eligible  military  health  care  beneficiaries.  Further-
more, this study will attempt to bank identified CTCs 
in order to perform additional molecular analyses in 
the future. The study‟s specific aims are to develop a 
simple, reliable, cost-effective, and clinically relevant 
breast cancer screening test in order to identify sub-
clinical disease early in its natural history in subjects 
at  risk  of  progression  to  clinically  apparent  disease 
over the ensuing decade. The study team‟s ultimate 
goal  is  to  decrease  the  treatment-related  morbidity 
and cause-specific mortality of breast cancer. 
Novel biomarkers also have dramatic potential 
to  improve  disease  detection,  amongst  other  end-
points,  in  the  breast  cancer  population.  Biomarkers 
represent  any  characteristic  that  can  be  objectively 
measured  and  evaluated  in  relation  to  the  point  of 
interest. Biomarkers can generally be applied to indi-
cate disease presence, progression, or recurrence, or 
more specifically tailored to a clinical situation of in-
terest  (i.e.  response  to  a  specific  therapy;  e.g.  Traz-
tuzumab adjuvant therapy in patients with Her2/neu 
expressing breast cancer). A broad definition of a bi-
omarker  is  any  physical,  functional,  or  biochemical 
indicator of a physiological or disease process that has 
diagnostic and/or prognostic utility [90].  
The  ability  to  study  and  treat  breast  cancer  in 
young, ethnically diverse women is hampered by a 
lack  of  novel,  reproducible,  accurate,  quantifiable, 
easily  obtainable  and  measureable  biomarkers  that 
correlate well with the presence of breast cancer early 
in the time course of cancer development (i.e., prior to 
development  of  a  clinically  identifiable  mass).  As 
highlighted above, there is no reliable way to screen 
for breast cancer in its earliest stages; consequently, 
the clinical presentation of disease is at a stage where 
reversal or optimal control is diminished. Similarly, 
there  are  no  generally  accepted  methods  for  moni-
toring  disease  progression  or  the  evaluating  accu-
rately  the  efficacy  of  potential  therapeutic  interven-
tions short of clinically observable signs or symptoms 
(e.g.,  reduced  size  and  activity  of  a  metastasis  on 
CT-PET scan). This can make disease follow-up more 
of a „wait-to-treat‟ practice, rather than a pro-active 
one. Through the use of biomarkers the potential to 
individualize risk assessment and diagnosis and fur-
ther advance into the era of “personalized medicine” 
may be realized. 
An  explosion  in  biomarker  discovery  and  re-
search has resulted from recent advances in molecular 
medicine.  Additionally, the advancements in molec-
ular  medicine  have  resulted  in  the  development  of 
new technologies aimed at biomarker discovery. Ge-
nomic, proteomic, and functional imaging tools have 
emerged, which have identified vast amounts of data 
concerning  single  nucleotide  polymorphisms,  mi-
croRNAs,  methylation  signatures,  as  well  as  genes 
and  master  control  genes  (homeobox  genes),  which 
might be valuable information in the form of predic-
tive or prognostic biomarkers in breast cancer. Novel 
approaches in the development of in-vitro diagnostic 
multi-marker index assays have shown that combin-
ing  multiple  biomarkers  with  interpretive  statistical 
algorithms has the potential to develop highly sensi-
tive, highly specific tests to indicate disease presence. 
While  the  development  of  novel  in-vitro  diagnostic 
tests is challenging, these tests also have the potential 
to  provide  a  widely  accessible  and  highly  accurate 
screening modality.  
Novel biomarkers (such as those obtained from a 
measurement of a readily obtained biological sample) 
that could predict disease presence earlier in the time 
course of breast cancer are a necessity, given the lim-
itations  noted  previously  with  the  current  breast 
screening paradigm. One recent example of this is an 
analytical platform in a growing field of metabolite 
molecular  diagnostics  combining  nuclear  magnetic 
resonance  and  two-dimensional  gas  chromatog-
raphy–mass  spectrometry.  A  metabolite  profil-
ing-based blood test has been shown to identify me-
tabolite signals in serum differentiating patients with 
breast cancer recurrence from those with no evidence 
of cancer with a sensitivity of 86%, specificity of 84%, 
and area under the receiver operating characteristics 
curve of 0.88 [91]. Over 50% of patients in that study 
were  accurately  predicted  to  have  recurrent  breast 
cancer  on  average  13  months  before  the  recurrence 
was clinically apparent, which is two times more sen-
sitive than monitoring serum tumor markers CA27.29 
and  CA  15-3  currently  in  use,  and  which  opens  a 
window  of opportunity of second  line  therapy at a 
much  earlier,  possibly  more  treatable  stage,  than  is 
possible with standard practice [91]. This emphasizes 
the  point  that  clinically  relevant  and  useful  bi-
omarkers must be quantifiable and correlate well with 
the clinical question intended to be answered. Addi-
tionally,  as  highlighted  above,  clinically  useful  bi-
omarkers should be relatively inexpensive, easily ex-
portable  throughout  the  community,  and 
non-invasive  so  that  they  can  be  measured  serially 
over time.  Journal of Cancer 2011, 2 
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Improving  the  quality  of  risk  assessment  and 
screening for breast cancer will likely require an ar-
mamentarium  of  tools  and  technologies  used  in  an 
algorithmic, staged approach. In all likelihood a com-
bination of algorithms and biomarkers for first stage 
risk identification and screening will be required to 
optimize estimation of risk and detection of disease, 
which would then support referral into a combination 
of  conventional  imaging  modalities  supported  by 
novel testing platforms such as CTCs. 
SUMMARY AND CONSENSUS 
RECOMMENDATIONS FOR ADVANCING 
BREAST CANCER RISK IDENTIFICATION 
AND SCREENING IN ETHNICALLY 
DIVERSE YOUNGER WOMEN 
Given  that  more  effective  treatment  strategies 
have  been  developed  for  breast  cancer  in  younger 
women, safe and effective screening could favorably 
impact disease-related survival in younger women if 
it were conducted at shorter intervals than in older 
women.  The  following  factors  were  considered  im-
portant  in  ensuring  continued  progress  in  reducing 
the burden of breast cancer among young women.  
  Development of more robust genetic predictors 
of disease; 
  Development  of  computational  approaches  di-
rected toward individual clusters of risk factors 
and modulatory genes; 
  Development  of  methods  by  which  epigenetic 
cumulative risk expression can be identified; 
  Development  of  inexpensive  technologies  by 
which  CTCs  can  be  identified,  isolated  and 
quantified in individuals; 
  Development of diagnostic platforms of markers 
of early breast cancer and pre-malignant lesions; 
  Designing and fostering clinical trials in young 
ethnically  diverse  female  populations  (such  as 
the U.S. military) with long term follow-up and 
assessment that can define the level of evidence 
for and promote the improvement in the above 
factors and variables. 
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